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Abstract
Background: Fabry disease is a rare X-linked lysosomal storage disorder caused by α-galactosidase A deficiency.
With the advancement of molecular diagnostic tools, more disease-causing mutations in α-galactosidase A (GLA)
have been identified in Fabry disease. We found a novel mutation in a Korean family with predominant renal
manifestations of the disease.
Case presentation: A 24-year-old man who wanted to donate a kidney to his 28-year-old brother with end-stage
renal disease of unknown cause was evaluated. The 24-year-old man underwent percutaneous renal biopsy because of
an accidentally found proteinuria. Electron microscopy of his renal biopsy showed numerous electron-dense multi-
lamellar inclusions in the epithelial cytoplasm, typical for Fabry disease. Clinical and laboratory evaluation including the
assessment of GLA enzyme activity and direct DNA sequencing in four members of the family were performed. Renal
biopsy findings in the two affected male patients were described. Re-evaluation of a renal biopsy specimen of his
28-year-old brother obtained when he was diagnosed with renal failure revealed a very focal area of suspicious
multilamellated structures in the Bowman’s space. DNA sequencing on the young man, his brother, and his mother
revealed a novel GLA gene mutation, c.263A > G (p.Tyr88Cys). The three all showed decreased α-galactosidase A activity.
Conclusion: A novel GLA mutation, c.263A > G (p.Tyr88Cys), was found in a Korean family with predominant renal
manifestations of Fabry disease.
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Background
Fabry disease (FD, OMIM#301500) is a rare, progressive,
X-linked, and multisystemic disorder characterized by
α-galactosidase deficiency resulting from mutations in
the α-galactosidase (GLA, OMIM*300644) gene at
Xq22.1 [1, 2]. The enzyme α-galactosidase A (GLA) is a
ubiquitous lysosomal acid hydrolase. Its deficient activity
can lead to progressive accumulation of globotriaosylcer-
amide and other glycosphingolipids within the lysosomes
of various cell types throughout the body, causing severe
and potentially life-threatening target-organ complica-
tions such as cardiovascular diseases, stroke, renal
failure, and eventually death [2].
The spectrum of clinical presentations in male patients
with FD varies widely, from severe classic phenotype to
relatively mild late-onset variant form [2, 3]. According
to previous reports, the clinical manifestations in the
classic form of FD starting from childhood or adoles-
cence include severe symptoms such as acroparesthesia,
hypohidrosis, corneal opacities, stroke, cardiac abnor-
malities, and renal disorders with high mortality [3–5].
On the contrary, the clinical manifestations of the vari-
ant form comprising almost 70 % of FD patients [6] are
usually mild and limited to the heart or kidney [3, 4].
Due to mild symptoms, these patients are often found
after disease progression. They only show findings of
focal segmental glomerular sclerosis. For such cases, the
key pathognomonic features such as electron-dense
multi-lamellar inclusions can be obscured by extensive
sclerosis on renal biopsy [4, 6]. As a result, it can be dif-
ficult to diagnose FD in time, particularly its variant
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form which is often undiagnosed or misdiagnosed as
other heart or kidney diseases [4].
Recently, there have been amazing advances in molecu-
lar diagnostics for FD. More than 700 mutations in GLA
gene have been identified, including missense mutations,
small deletions/insertions, splice mutations, and large
gene rearrangements [7]. These are listed in the Human
Gene Mutation Database (http://www.hgmd.cf.ac.uk/),
Fabry Database (http://fabry-database.org/), and ClinVar
(http://www.ncbi.nlm.nih.gov/clinvar/). New mutations
are still being discovered.
In the present study, we identified a novel mutation,
Tyr88Cys, in GLA in a Korean family with late-onset FD
variant. We also discussed their clinicopathologic feau-
tures and the molecular diagnosis of FD.
Case presentation
Subjects and kidney biopsy procedure
We studied four members of a Korean family. Clinical
and physical examinations were performed for each
member. All family members gave written consent be-
fore we obtained blood and kidney samples from them.
Percutaneous renal biopsy was done by nephrologists
under ultrasonographic guidance using an automated bi-
opsy gun as previously described [8]. Histopathologic
diagnosis on each sample was made comprehensively
based on all clinical data and pathologic findings.
Analysis of genomic DNA and GLA enzyme activity
Genomic DNA samples were isolated from peripheral
white blood cells using QIAamp DNA Blood Mini Kit
(Qiagen, Hilden, Germany). For sequencing, samples
were pooled in an equimolar ratio. Genomic DNA
library (10 pM) containing 1 % PhiX control library were
prepared and sequenced on a MiSeq platform (Illumina,
San Diego, CA) using MiSeq v2 chemistry. Next gener-
ation sequencing (NGS) data analyses were performed
using bioinformatics pipeline of Labgenomics Co. Ltd.
(Gyeonggi-do, Republic of Korea). Briefly, the paired-end
sequencing reads of 250 bases in length were binned for
each sample according to the index and mapped to the
human genome assembly (hg19). Burrows-Wheeler
Aligner (BWA) was used to align these sequences to the
human genome allowing up to 2 base mismatches
(RefSeq NM_000169). Pathogenic variants and variants
of unknown significance (VUS) detected by NGS were
confirmed by Sanger sequencing analyses with AB
3730XL DNA Analyser (Life Technologies, Carlsbad,
CA, USA) in accordance with the manufacturer's in-
structions. Sequencing results were searched against data
of Korean exomes obtained from Labgenomics, data
from Korea National Institution of Health (KNHIH),
dbSNP, and 1000 Genomes Project databases. To deter-
mine whether the newly discovered mutation in GLA
might contribute to FD, prediction tests including
Polyphen-2 and MutationTaster were used as described
previously [9–11].
For all subjects, we assessed lysosomal GLA enzyme in
the leukocytes by fluorometric assay using substrate
4-MU-α-D-galactopyranoside [12, 13]. Enzyme level was
expressed as nmole of cleaved substrate per milligram of
protein per hour at 37 °C. The enzyme activity was
normalized to the activity of the control (100 %).
Results
The clinicopathologic features of these patients includ-
ing enzymatic and genetic analysis results are summa-
rized in Table 1. The pedigree of the family is shown in
Fig. 1. A 24-year-old man (patient 1) was evaluated
voluntarily to donate a kidney to his 28-year-old brother
(patient 2) who had end-stage renal disease (ESRD) and
had been undergoing peritoneal dialysis for the previous
2 years. Patient 1 had an unremarkable medical history
without medications. His assessment was overall satis-
factory except a proteinuria of 871 mg/day (reference
range, < 150 mg/day) that was discovered incidentally. A
kidney biopsy was performed in view of the unaccount-
able proteinuria.
In 2014, which was two years ago before patient 1’s visit,
patient 2 (his brother) had presented at the age of 26 years
with nephrotic-range proteinuria (24 h urine protein,
8486.4 mg/day) and renal insufficiency with serum cre-
atinine of 8.06 mg/dL (reference, 0.50–1.20 mg/dL). At
that time, a renal biopsy was performed and the finding
was glomerulosclerosis with moderate to severe
Table 1 Clinicopathologic features of the four patients described in this case report
Subject No. Age/Sex Clinical findings α-galactosidase A c.263A > G mutation Kidney biopsy findings
Patient 1 24/M Proteinuria Decreased (2.2 nmol/hr/mg protein) Present Consistent with FD
Patient 2 28/M End-stage renal disease,
hypertension, left
ventricular hypertrophy
Decreased (4.0 nmol/hr/mg protein) Present Consistent with FD
Patient 3 54/F Mild proteinuria, diabetes Slightly decreased (32.6 nmol/hr/mg
protein)
Present Unavailable
Individual 4 26/M Unremarkable Normal (43.4 nmol/hr/mg protein) Not present Unavailable
FD Fabry disease, F female, M male, No, number
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tubulointerstitial fibrosis indicating advanced renal failure.
As a result, plans to initiate dialysis were immediately
made. Considering patient 1’s proteinuria, there was
ample room for doubt regarding familial kidney disease.
Accordingly, patient 2’s previous renal biopsy slides and
medical records were re-reviewed.
The mother (patient 3) of patients 1 and 2 was a 53-
year-old female who had been diagnosed with diabetes
10 years earlier. She had been completely asymptomatic.
However, based on her sons’ results, she also underwent
screening. Results revealed normal renal function with
slightly elevated proteinuria (154.8 mg/day). Renal
biopsy in patient 3 was not performed. Individual 4, the
second son of patient 3, showed normal results for all
laboratory findings, including renal function.
Apart from renal involvement, the affected patients (1, 2,
and 3) had no other clinical manifestations such as periph-
eral neuropathy, angiokeratoma of skin, corneal opacities,
abdominal pain, diarrhea, or arrhythmias. Patient 2 only
showed high blood pressure (165/100 mmHg) and left
ventricular hypertrophy on echocardiographic examination.
Renal biopsy from patient 1 revealed 12 glomeruli with
only a subtle change on microscopic examination. How-
ever, nothing was significant (Fig. 2a). The glomerular
epithelial cells were swollen and showed somewhat
bubbly appearance with vague vacuoles. The renal
tubules, interstitium, and blood vessels were unremarkable.
There was no immune deposition on immunofluorescence
for immunoglobulins. Electron microscopy revealed typical
electron-dense multi-lamellar inclusions and zebra bodies
in the cytoplasm of the epithelial cells (Fig. 2b).
Fig. 1 The family pedigree. The shaded squares indicate affected men
(patients 1 and 2). The circle with a dot indicates heterozygous woman
(patient 3). ESRD, end-stage renal disease; y, years
Fig. 2 Light and electron microscopic findings of renal biopsies from patients 1 and 2. a On microscopic examination of patient 1, there are some
vague vacuolizations of podocytes (black arrowhead), although he showed normal renal function and proteinuria (H&E stain, ×400). b Multilamellated
myelin figures (white arrowhead), so-called zebra bodies—which are typical findings in Fabry disease—are found in patient 1’s podocytes on electron
microscopy. c Similar vacuolated epithelial cells (black arrowhead) are found in the relatively preserved glomerulus of patient 2, whereas
most glomeruli are damaged by sclerosis (H&E stain, ×400). d A focal area showing a tiny, dark–stained, round multilamellar inclusion (white arrowhead)
on the electron microscopy result for patient 2
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With the suspicion of a familial disease, we punc-
tiliously reviewed patient 2’s renal biopsy results. His
biopsy specimen contained 9 glomeruli which showed
7 global and segmental glomeruloscleroses. There was
moderate to severe tubulointerstitial damages, includ-
ing mononucleocyte and neutrophil infiltration, inter-
stitial fibrosis, and tubular atrophy. There was no
immune deposition on immunofluorescence staining.
However, detailed observation of the unaffected glom-
eruli revealed characteristic vacuolization of epithelial
cells (Fig. 2c), which had been missed 2 years ago
due to profound glomerular damage. On electron mi-
croscopy, there was a very focal area with suspicious
multilamellated structures in the Bowman’s space
(Fig. 2d). These findings in patients 1 and 2 were
consistent with Fabry nephropathy.
DNA sequencing for GLA showed that patients 1, 2,
and 3 carried a c.263A > G (p.Tyr88Cys) mutation in
exon 2 (Fig. 3). This mutation has not been previously
reported in Genbank or other mutation database of FD.
Genetic analysis in individual 4 was unremarkable. To
confirm the potential role of this mutation, we used
tools to predict the possible impact of an amino acid
substitution on the structure of a protein for further
analysis. The Polyphen-2 scores for the Tyr88Cys muta-
tion in GLA ranged from 0.990 to 1.000, suggesting that
the mutation was likely to damage the protein. The
score for amino acid changes and the probability value
drawn by MutationTaster were 194 and 0.999 (the pre-
diction was highly secure), respectively. These results
strongly suggest that the novel mutation might have a
damaging effect on the enzyme’s structure.
From our determination of the GLA enzyme in blood
leukocytes, patient 1 showed a decreased GLA protein
level (at 2.2 nmol/h/mg, average of 1,000 normal con-
trols: 62.3 nmol/h/mg; reference: 35–100 nmol/h/mg)
with decreased GLA activity (23.1 %, average of 1,000
normal controls: 92.0 %; reference: 85–95 %), confirming
enzymatic defect of GLA. Protein level and activity of
GLA in patient 2 were 4.0 nmol/h/mg protein (average
of 1,000 normal controls, 66.8 nmol/h/mg) and 22.3 %
(average of 1,000 normal controls, 93.2 %), respectively.
Fig. 3 Electropherogram of exon 2 of α-galactosidase A in this family with Fabry nephropathy. The analysis shows a mutation of A > G at nucleotide
263, resulting in an amino acid substitution p.Tyr88Cys
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Patient 3 was thought to be a healthy female carrier.
However, her GLA protein level and activity were
32.6 nmol/h/mg protein (average of 1,000 normal con-
trols, 79.0 nmol/h/mg) and 89.6 % (average of 1,000 nor-
mal controls, 92.3 %), respectively, which were below
normal ranges, indicating a heterozygous state. The pro-
tein level and activity of GLA enzyme in individual 4
were 43.4 nmol/h/mg protein (average of 1,000 normal
controls, 61.6 nmol/h/mg) and 94.0 % (average of 1,000
normal controls, 93.2 %), respectively, which were within
normal ranges.
Conclusion
In this report, we identified a new GLA mutation
(c.263A > G p.Tyr99Cys) in a Korean family with pre-
dominant renal involvement of late-onset FD. We have
deposited this new mutation data to the Fabry Database
(http://fabry-database.org/, ID: 329). Although these
family members shared the same GLA mutation,
substantial differences in clinicopathologic features and
residual enzyme activities were noticed, which can be
potential pitfall for proper early diagnosis of FD,
especially for its late-onset variant.
GLA mutation in coding sequence can result in amino
acid changes, which is likely to alter protein conform-
ation and subsequent functional defect of the GLA
enzyme [14]. The 88 Tyr amino acid belongs to the
group of amino acids buried in the hydrophobic core
likely involved in protein folding [14, 15]. Although the
current study did not cover the functional pathogenesis
of Tyr88Cys, the potential deleterious effect of the
Tyr88Cys mutation was predicted in this study using
bioinformatics tools Polyphen-2 and MutationTaster.
However, further study on the functional alteration
resulted from Y88C mutation is still needed.
The genotype-phenotype correlation is not perfect in
FD [5]. In this report, two brothers (patients 1 and 2)
were only 4 years apart in age. However, they demon-
strated somewhat different clinical courses. Patient 2
was already on peritoneal dialysis due to resultant ESRD
while patient 1 only had mild proteinuria with normal
renal function, although they had similar levels of GLA.
This supports the notion that environmental and other
genetic factors can affect the disease severity and pheno-
typic variability of FD [5]. This is consistent to the find-
ings of a previous study showing marked intra-familial
variability in residual GLA enzyme activity and the nat-
ural disease course of FD [16]. The GLA activity in
patient 3, the mother, was slightly below the normal
range without evident clinical symptoms. Female carriers
of GLA mutations in FD have been considered as
asymptomatic originally. However, it is now accepted
that heterozygous females may also develop mild to
severe clinical manifestations of FD [5, 17]. The
characteristic presentations including delayed onset and
a higher probability of a single organ involvement have
been thought to be due to random X chromosome
inactivation [18, 19].
Recently found novel GLA mutations are mainly from
patients with mild and late-onset FDs [13, 20]. Charac-
teristically, late-onset FD has renal or cardiac involve-
ment without characteristic skin lesions or pain crises.
FD is often diagnosed when patients are in their 50 s or
60 s [11].
This report shows an important point regarding
kidney biopsy. In patient 1 who had only proteinuria,
biopsy played a valuable role in diagnosing the FD
missed in his family member. Although his kidney speci-
men demonstrated almost normal appearance in light
microscopy examination, the electron microscopy clearly
demonstrated lamellated myelin structures and con-
firmed the diagnosis of typical FD. On the contrary, we
missed the FD findings in patient 2’s kidney biopsy
2 years ago due to extensive sclerotic glomerular dam-
age. The lamellated structure covered on the glomerular
surface may inhibit glomerular filtration and result in
endothelial injury [15]. Subsequently, endothelial cells in
the vicinity of any damaged podocytes are submitted to
additional hydraulic forces, leading to glomerular
collapse and sclerotic change [15]. This diffuse and pro-
gressive destruction of the kidney structure may make it
difficult to recognize the typical FD findings. Thus, it is
important to secure the minimum requirement of pre-
served glomeruli to obtain accurate pathologic diagnosis.
For female patients 3 with minimal proteinuria, it might
be necessary to perform renal biopsy in order to identify
whether the proteinuria was due to FD or diabetes. The
majority of female carriers do not develop renal disease
with glycosphingolipids deposition. However, some clin-
ically normal heterozygous females have typical kidney
biopsy findings [21].
Early diagnosis of FD is crucial for commencing early
enzyme replacement therapy and improving the natural
disease course by preventing progressive organ failure
[22]. Although diabetes, hypertension, and chronic
glomerulonephritis are the most common causes of
ESRD, the causes of primary renal disease in more than
20 % of patients with ESRD are still uncertain [23, 24].
Therefore, it is reasonable to bestow some consideration
on screening for FD in patients with renal failure of un-
known causes at an early age. In male patients, the diag-
nosis of FD can be made based on markedly deficient
GLA enzyme activity in plasma or leukocytes and GLA
mutations [9]. In order to identify affected females, it is
important to combine biochemical assays with molecular
analyses of the GLA gene [16, 17]. Considering that FD
has progressive effects on various organs, vital organ
damage would have already begun regardless of the
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activity of GLA enzyme. This implies that biopsy of the
involved organ could help us identify the extent of FD
and start therapy accordingly.
Because the parents of patient 3 have already passed
away with unspecified causes at the ages of 62 and
67 years, respectively, it is impossible to know at which
generation that this mutation started in this family.
However, patient 3 had seven siblings. Her two older
brothers died of renal disease that required dialysis at
the ages of 31 and 57 years, respectively. Molecular test-
ing for GLA gene for patient 3’s youngest brother was
normal. Tests for other siblings are now being carried
out. Past history of her two brothers suggests the possi-
bility that the patient 3’s mother was a carrier of the mu-
tant GLA gene. However, it is also possible that this
mutation is a de novo mutation or that either the mother
or the father of patient 3 is a germ line mosaic for the
mutation [25, 26]. In patients 1 and 2, the enzymatic
activity of GLA needs to be tested serially so that treat-
ment can be started before other organ involvement be-
comes irreversible. The female carrier patient 3 also
needs to be followed up closely for the possibility of her
developing FD-related symptoms. A request for enzyme
replacement therapy has been submitted to The Health
Insurance Review and Assessment Service.
In summary, this report revealed the presence of a
c.263A > G p.Tyr88Cys mutation in exon 2 of GLA gene
in a Korean family with Fabry nephropathy. The detec-
tion of this new mutation in GLA highlights the notion
that there is no single predominant mutation in FD. This
report also described the possibility that distinctive find-
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